-	Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-150003	Application No. 10/010,283
		Applicant Carl-Axel Bauer et al.		
	(Use several she (37 CFR §1.98(b))	ets if necessary)	Filing Date November 13, 2001	Group Art Unit 1617

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/JK/	Al	Ankerst et al., "Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma." Pulm Pharmacol Ther., 16:147-51, 2003.
	A2	Arvidsson et al., "Inhaled formoterol during one year in asthma: a comparison with salbutamol," Eur Respir J, 4:1168-1173, 1991.
	A3	Aubier et al., "Salmeterol/Fluticasone propionate (50/500 μg) in combination in a Diskus® inhaler (Seretide®) is effective and safe in the treatment of steroid-dependent asthma," Respir. Med. 93:876-884, 1999.
	A4	Bartow et al., "Formoterol: An Update of its Pharmacological Properties and Therapeutic Efficacy in the Management of Asthma," Drugs, 55(2):303-322, 1998.
	A5	Bond, "A strategy that works," New Zealand Medical Journal, p. 369, 28 August 1991.
	A6	"The British Guidelines on Asthma Management 1995 Review and Position Statement," Thorax, 52(Suppl 1):S1-21, 1997.
	A7	Collins et al., "The Use of Corticosteroids in the Treatment of Acute Asthma," Quarterly Journal of Medicine, New Series, XLIV:259-73, 1975.
	A8	Corren et al., "Twelve-Week, Randomized, Placebo-Controlled, Multicenter Study of the Efficacy and Tolerability of Budesonide and Formoterol in One Metered-Dose Inhaler Compared with Budesonide Alone and Formoterol Alone in Adolescents and Adults with Asthma," Clinical Therapeutics, 29(5):823-843, 2007.
	A9	Costain et al., "Guidelines for management of asthma in adults: I—chronic persistent asthma," BMJ, 301:651-653, 1990.
	A10	Devidayal et al., "Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma," Acta Paediatr, 88:835-840, 1999.
	A11	Ebden et al., "Comparison of two high dose corticosteroid aerosol treatments, beclomethasone dipropionate (500 μg/day) and budesonide (1600 μg/day), for chronic asthma," Thorax, 41:369-874, 1986.
	A12	Ellul-Micallef and Johansson, "Acute Dose-Response Studies in Bronchial Asthma with a New Corticosteroid, Budesonide," Br. J. Clin. Pharmac., 15:419-422, 1983.
	A13	Ellul-Micallef et al., "Budesonide: A New Corticosteroid in Bronchial Asthma," Eur J Respir Dis., 61:167-173, 1980.
	A14	Engel et al., "Single-dose inhaled budesonide in subjects with chronic asthma," Allergy, 46:547-553, 1991.
	A15	
	A16	1999.
	A17	"Foradil: Fast relief that lasts," Ciba-Geigy Limited, Switzerland, Medical and Pharmaceutical Information, 1993
$\bigvee$	A18	Pneumology, Freiberg, Germany, September 1989.
/JK/	A19	Hett et al., "Large-Scale Synthesis of Enantic- and Diasteromerically Pure (R,R)-Formoterol," Org. Process Res. Dev., 2:96-99, 1998.
Examiner Sign	nature /.l	enpifer Kim/ Date Considered 03/02/2009

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-150003	Application No. 10/010,283
Information Disclosure Statement by Applicant		Applicant Carl-Axel Bauer et al.		
	(Use several sheet (37 CFR §1.98(b))	ts if necessary)	Filing Date November 13, 2001	Group Art Unit 1617

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	Document
/JK/	A20	Jackson et al., "Benefit-Risk Assessment of Long-Acting $\beta_2$ -Agonists in Asthma," Drug Safety, 27(4):243-270, 2004.
	A21	Kesten et al., "A Three-Month Comparison of Twice Daily Inhaled Formoterol Versus Four Times Daily Inhaled Albuterol in the Management of Stable Asthma," Am Rev Respir Dis, 144:622-625, 1991.
	A22	Kumar et al., "Transient Effect of Inhaled Fluticasone on Airway Mucosal Blood Flow in Subjects with and without Asthma," Am J Respir Crit Care Med, 161:918-921, 2000.
	A23	Lampa et al., "Antitracheobronchospastic Interaction In Vitro and In Vivo between Salbutamol and Flunisolide," Drugs Exptl. Clin. Res., XI(9):653-658, 1985.
	A24	Li, "Key Points of the new asthma guidelines," The Journal of Respiratory Diseases, 18:823-838, 1997.
	A25	McDonald et al., "Evaluation of the combination inhaler of salbutamol and beclomethasone dipropionate in the management of asthma," Curr. Med. Res. Opin., 11(2), 1988.
	A26	McFadden "Inhaled Glucocorticoide and Acute Aethma: Theraneutic Breakthrough or Nonenecific
	A27	
	A28	Monthly Index of Medical Specialties (MIMS), Bronchodilators and anti-inflammatories, December 1991.
	A29	Monthly Index of Medical Specialties (MIMS), Respiratory System, December, 1991.
	A30	Moore et al., "Long-acting Inhaled β <sub>2</sub> -Agonists in Asthma Therapy," Chest, 113:1095-1108, 1998.
	A31	Nana et al., "High-Dose Inhaled Budesonide May Substitute for Oral Therapy After an Acute Asthma Attack," Journal of Asthma, 35:647-655, 1998.
	A32	National Asthma Education and Prevention Program, "Guidelines for the Diagnosis and Management of Asthma," Expert Panel Report 2 July 1997 No. 97-4051.
	A33	Nuholm at al. "Thereneutic advantages of twice daily over four-times daily inhalation hudesonide
	A34	The Patents Act 1953 Exhibit "CRWB1." 1998
	A35	The Patents Act 1953 Exhibit "CRWB3." 1998
	A36	The Patents Act 1953 Exhibit "CRWB4." 1998
	A37	The Patents Act 1953 Exhibit "CRWB5." 1998
	A38	The Patents Act 1953 Exhibit "CRWB6." 1998
	A39	J., 13:988-992, 1999.
V	A40	Rabe et al., "Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomized controlled, double-blind study," Lancet, 368:744-753, 2006.
/JK/	A41	Rabe et al., "Budesonide/Formoterol in a Single Inhaler for Maintenance and Relief in Mild-to- Moderate Asthma," Chest, 129:246-256, 2006.

Examiner Signature /Jennifer Kim/	Date Considered 03/02/2009
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	t in conformance and not considered. Include copy of this form with

	Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office		Application No. 10/010,283
Information Disclosure Statement by Applicant		Applicant Carl-Axel Bauer et al.		
	(Use several sheets if necessary)		Filing Date	Group Art Unit
Į	(37 CFR §1.98(b))		November 13, 2001	1617

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/JK/	A42	Rees, "β <sub>2</sub> Agonists and asthma," BMJ, 302:1166-1167, 1991.
I	A43	Rosenborg et al., "Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics," Eur J. Clin Pharmacol., 56:363-370, 2000.
	A44	Rodrigo et al., "Inhaled Flunisolide for Acute Severe Asthma," Am J Respir Crit Care Med, 157:698-703, 1998.
	A45	Rodrigo et al., "Acute Asthma in Adults: A Review," Chest, 125:1081-1102, 2004.
	A46	Ryrfeldt et al., "Pulmonary disposition of the potent glucocorticoid budesonide evaluated in an isolated perfused rat lung model," Biochem Pharmacol., 38:17-22, 1989.
	A47	Schuh et al., "A Comparison of Inhaled Fluticasone and Oral Prednisone For Children with Severe Acute Asthma," New England Journal of Medicine, 343:689-694, 2000.
	A48	Sears et al., "Regular inhaled beta-agonist treatment in bronchial asthma," Lancet, 336:1391-1396, 1990.
	A49	Shepherd et al., "Regular Versus Symptomatic Aerosol Bronchodilator Treatment of Asthma", Br. J. Dis. Chest, Vol. 75, pages 215-217 (1981).
	A50	Sue et al., "A Comparison of Intravenous Hydrocortisone, Methylprednisolone, And Dexamethasone in Acute Bronchial Asthma," Annals of Allergy, 56:406-409, 1986.
	A51	Sykes et al., "A study of the duration of the bronchodilator effect of 12 ug and 24 ug of inhaled formoterol and 200 ug inhaled salbutamol in asthma," Respir. Med., 84:135-138, 1990.
	A52	Tan et al., "Systemic Corticosteroid Rapidly Reverses Bronchodilator Subsensitivity induced by Formoterol in Asthmatic Patient", Am. J. Respiratory and Critical Care Medicine, 156:28-35, 1997.
	A53	Tattersfield et al. on behalf of the Facet International Study Group, "Exacerbations of Asthma," Am J Respir Crit Care Med, 160:594-599, 1999.
	A54	The Dialog Corporation, "Formoterol launched in Switzerland", Accession No: S002557609000, 10/31/1990.
	A55	The Merck Manual of Diagnosis and Therapy, 16th edition, 1992, page 653.
	A56	Trechsel, "Foradil in medical practice: 7 case studies," Ciba-Geigy Limited, Switzerland (1992).
	A57	Treschel, AM Conference Report, A new long-acting beta-stimulator 1991
	A58	U.S. Department of Health and Human Services, "Practical Guide for the Diagnosis and Management of Asthma," October 1997 NIH Publication No. 97-4053.
	A59	Vanzieleghem et al., "A comparison of budesonide and beclomethasone dipropionate nasal aerosols in ragweed-induced rhinitis," J. Allergy Clin. Immunology, 79:887-892, 1987.
$\forall$	A60	1991.
/JK/	A61	Wallin et al., "Formoterol, a new long acting beta2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma," Thorax, 45:259-261, 1990.

Examiner Signature	Date Considered
/Jennifer Kim/	03/02/2009
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	t in conformance and not considered. Include copy of this form with